CHAI Discovery

Building frontier artificial intelligence to predict and reprogram the interactions between biochemical molecules.

Building frontier artificial intelligence to predict and reprogram the interactions between biochemical molecules.

Dimension Capital raises an $800 million third fund, expanding its bet on companies at the intersection of science and compute. The fund is 60% larger than its $500 million second vehicle, announced 18 months earlier. The portfolio includes AI drug-development startup Chai Discovery, anti-aging company New Limit, Modal Labs, and Anthropic; Dimension also receives Anthropic shares after the AI company acquires portfolio company Coefficient Bio.

Jul 2026 · TechCrunchNews article

OpenAI researcher Miles Wang is leaving the company to launch a startup developing AI models for drug discovery, with several OpenAI researchers expected to join. Sources say Wang is discussing a roughly $200 million raise at a $2 billion valuation, with Lightspeed in talks to lead, though Wang disputes the reported figures and company description and discussions remain unsettled. Sources say the startup may seek new uses for existing drugs, including candidates that failed trials.

Jul 2026 · TechCrunchNews article

Chai Discovery grows from an OpenAI-backed startup into a prominent AI drug discovery company, with deals involving Eli Lilly and Pfizer. Its trajectory runs from its beginnings in OpenAI’s offices to partnerships with the pharmaceutical companies.

Jan 2026 · TechCrunchNews article

Chai Discovery announces a $130 million Series B round to expand its AI molecular discovery platform.

Dec 2025 · CHAI DiscoveryNews article